• J E Ramos de Carvalho, R O Schlingemann, M Oranje, F J Bemelman, and M J van Schooneveld.
• Department of Ophthalmology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. j.e.decarvalho@amc.uva.nl.
• Int Ophthalmol. 2018 Feb 1; 38 (1): 399-407.

AbstractPurtscher-like retinopathy, a rare manifestation of systemic thrombotic microangiopathy, is a potentially visually debilitating condition with no effective proven treatment. Distinct pathogenic pathways have been proposed as etiological factors. We revisit the etiology of Purtscher-like retinopathy based on the rapid response and profound visual improvement after initiation of systemic intravenous eculizumab, an inhibitor of the complement cascade, in a patient with Purtscher-like retinopathy secondary to familial atypical hemolytic uremic syndrome (aHUS) due to a mutation in complement factor H. We hypothesize that the efficacy of eculizumab in this patient provides evidence for pathogenic events in the retina similar to those encountered in the renal microvasculature of aHUS patients, namely complement-mediated thromboembolization as a result of activation of the complement cascade in endothelial cells with release of tissue factor and development and amplification of a procoagulant state. To the best of our knowledge, this is the first report in the literature of eculizumab as an effective therapeutic strategy in Purtscher-like retinopathy.

29 keywords...

hide…